Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Laekna HK$236 million placement of shares
We advised Laekna on the placement of new shares
Alignment Healthcare $330 million convertible senior notes offering
The convertible notes are due 2029
ACELYRIN $150 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
Cardinal Health $2.9 billion notes offering
The investment-grade notes are due 2026, 2029, 2034 and 2054
Omnicell $172.5 million convertible senior notes offering
The convertible senior notes are due 2029
Horizon Mutual Holdings debut $600 million senior notes offering
The investment-grade notes are due 2034
GSK strategic alliance with Vesalius Therapeutics
We advised GSK on the transaction
Elevance Health $5.2 billion senior notes offering
The investment-grade notes are due 2026, 2030, 2031, 2035, 2055 and 2064
Molecular Partners $20 million follow-on offering
The ADSs are listed on the Nasdaq Global Select Market
PL Developments exchange offer and consent solicitation
The exchange offer included the issuance of new PIK toggle senior secured notes due 2029